Lexeo Therapeutics, Inc. Share Price & Technical Analysis
LXEO · $5.11 (-2.29%)
Healthcare / Biotechnology
$5.11
-2.29%
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a …
Price chart
Seasonality
May has 1 positive and 2 negative years (last 4 years shown)
-11% return in May, 1% avg return in past 3 year May month.
-55% return in 2026, 29% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -25% | -3% | -19% | 2% | -11% | – | – | – | – | – | – | – | -55% |
| 25 | -19% | -45% | 21% | 15% | -32% | 43% | 18% | 7% | 38% | 52% | 5% | 3% | 103% |
| 24 | 32% | -14% | 5% | -22% | 34% | -5% | -21% | -8% | -22% | -12% | 3% | -20% | -49% |
| 23 | – | – | – | – | – | – | – | – | – | – | 34% | 0% | 34% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company is also developing LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, LX1020, and LX1021, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has a license agreement with Cornell University to conduct the Phase 1/2 clinical trial of LX1001, as well as support the development of the LX1004 program; a research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$451.50M
P/E ratio
—
52W high
$10.99
52W low
$2.51
Volume
4,61,195
Beta
1.53
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Lexeo Therapeutics, Inc. share price today?
- Lexeo Therapeutics, Inc. (LXEO) last traded around $5.11 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does LXEO have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for LXEO. Download the app for real-time alerts.
- How can I analyze Lexeo Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.